Does Domperidone Increase Breastmilk Production?
Yes, domperidone increases breast milk production in lactating women, particularly in mothers of preterm infants with insufficient milk supply, and is recognized as a galactagogue that can be used safely with appropriate monitoring.
Evidence-Based Recommendation
Guideline Support
The 2020 Association of Anaesthetists guideline explicitly states that domperidone is "used as a galactagogue, so may increase milk supply" 1. The guideline notes that when taken orally, levels in milk are low due to first-pass hepatic and intestinal metabolism, and importantly recommends ensuring women have access to a breast pump if there is any delay in feeding their infant 1.
Research Evidence - Efficacy
The most recent and highest quality evidence comes from a 2024 Bayesian network meta-analysis that provides the strongest support for domperidone's efficacy 2:
- In preterm mothers: Domperidone significantly increased breast milk volume compared to both metoclopramide (MD = 82.84 mL/day, 95% CI: 37.04-118.95) and placebo (MD = 88.30 mL/day, 95% CI: 59.48-118.62)
- In term mothers: The evidence was insufficient to demonstrate clear benefit over placebo or metoclopramide
- Metoclopramide showed no superiority over placebo in either group
A 2021 systematic review and meta-analysis corroborates these findings, showing domperidone increased daily milk volume by 90.53 mL/day (95% CI: 65.42-115.64) in mothers of preterm infants with low milk supply 3.
Safety Profile
No serious adverse events were reported across multiple studies 2, 3, 4, 5, 6. The 2021 meta-analysis found no difference in maternal side effects between domperidone and placebo (RR = 1.20,95% CI: 0.74-1.97) 3.
However, a 2023 Australian survey of real-world use revealed important safety considerations 7:
- 48% of women reported side effects (weight gain 25%, headaches 17%, dry mouth 13%)
- Side effects were dose-related (38% at ≤30 mg/day vs 73% at >61 mg/day)
- 9% stopped treatment due to side effects
Clinical Application Algorithm
1. Patient Selection
- Best candidates: Mothers of preterm infants with documented insufficient milk supply
- Uncertain benefit: Mothers of term infants (insufficient evidence)
- Prerequisites: Ensure proper breastfeeding technique and frequent milk expression have been optimized first
2. Dosing Strategy
Based on the pharmacokinetic data 1:
- Standard dose: 10 mg three times daily (30 mg/day total)
- Timing: After breastfeeding or milk expression
- Duration: Typically 7-14 days, though some women may require longer treatment
- Maximum dose: Generally should not exceed 30-40 mg/day for lactation (higher doses associated with increased side effects)
3. Monitoring Requirements
- Assess milk volume increase after 7 days
- Monitor for side effects (headache, dry mouth, weight gain, palpitations)
- Ensure breast pump access if separation from infant occurs
- Consider discontinuation if no benefit after 14 days
4. Expected Outcomes
- Anticipated increase: 80-90 mL/day in responsive patients
- Time to effect: Usually within 3-7 days
- Patient-reported effectiveness: 45% report "very" or "extremely effective" 7
Important Caveats
FDA Status Warning
Critical caveat: Domperidone is not FDA-approved for any indication in humans in the United States 8. The FDA drug label explicitly states it is "not for use in humans" and that "the safety of domperidone in lactating women and their nursing children has not been evaluated" 8. This creates a significant regulatory consideration for U.S. practitioners, though the drug is widely used internationally.
Contraindications
- History of cardiac arrhythmias or prolonged QTc
- Prolactinoma
- Concurrent use of strong CYP3A4 inhibitors
- Gastrointestinal hemorrhage or obstruction
Transfer to Infant
The guideline reassures that milk levels are low (milk:plasma ratio 0.25, relative infant dose 0.01-0.35%) due to extensive first-pass metabolism 1. The drug is 93% protein-bound with a half-life of 7-14 hours 1.
Practical Considerations
When domperidone works best: The evidence strongly supports use in mothers of preterm infants who have already attempted non-pharmacological interventions (proper latch, frequent expression, adequate hydration, rest). The 2021 RCT showed that 71.7% of mothers increased milk production with counseling alone before needing pharmacological intervention 4, emphasizing the importance of optimizing breastfeeding management first.
Alternative consideration: If domperidone is unavailable or contraindicated, metoclopramide is also recognized as a galactagogue 1, though the evidence shows it is less effective than domperidone in preterm mothers 2, 3.
Breastfeeding outcomes: One high-quality RCT demonstrated that 95% of babies in the domperidone group were exclusively breastfeeding at hospital discharge compared to 52.4% in the placebo group (p = 0.008) 4, suggesting meaningful clinical impact beyond just milk volume.